



PATIENT

Walter O'Shannon

SPECIES

Canine

BREED

Chihuahua

SEX

Male Neutered

AGE

13 years

WEIGHT

7lbs

INTERPRETED BY

Maggie Machen
 Lamy, DVM, DACVIM
 (Cardiology)

IMAGING PERFORMED BY

Jenna Walsh, CVT

HOSPITAL NAME

Hello Vet for Pets
 LLC

REFERRING VET

Dr. Christensen

INVOICE

29213

DATE

2/23/23

PRESENTING CLINICAL SIGNS

History: Grade 5/6 heart murmur. Patient has experienced episodes of twitching and lethargy with no apparent cause.
 -Current medications: Furosemide 12.5mg 1/2 BID, Vetmedin 1.25mg 1 tab, 1/2 tab in pm.

RADIOGRAPHIC FINDINGS *NOTE: Images submitted for supplemental cardiac information only.
 Cardiomegaly with LA dilation. No obvious evidence of CHF.

ELECTROCARDIOGRAPHIC FINDINGS *Note: Single lead ECGs are evaluated as a rhythm strip. Morphology/MEA cannot be definitively commented on.
 A single lead ECG is available; 50mm/s, 20mm/mV. The average heart rate is 170bpm (range 158-200bpm). The rhythm is sinus in origin, with a p for every QRS complex and vice versa. The QRS morphologies are positive. No ectopic beats, pauses or dysrhythmias observed.
 ECG diagnosis: Normal sinus rhythm with respiratory variation.


ECHOCARDIOGRAM FINDINGS

2D, m-mode, color flow and doppler imaging is available. The mitral valve is thickened with mild prolapse into the left atrial lumen. There is severe eccentric mitral regurgitation present. The MR velocity is normal. There is severe left atrial enlargement. There is mild left ventricular dilation. Left ventricular systolic function is hyperdynamic. Mild right atrial and ventricular dilation (subjective). Mild thickening of the tricuspid valve with significant prolapse. Mild to moderate TR. Velocity consistent with moderate pulmonary hypertension. There is normal systolic flow velocity across the aortic valve. The aortic valve appears normal with no AI. The main pulmonary artery is mildly enlarged. The pulmonic valve is normal in appearance. No PI. No pericardial/pleural effusion or cardiac masses are seen.

CARDIAC CHART

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	6.5	4.1	2.2	2.2	59	90	NM
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	175	1.1	0.95	3.2	2.2	2.8	1.2
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)

Adapted from June Boon, Veterinary Echocardiography, 1998
 Rishniw M and Hollis NE, J Vet Intern Med 2000; 14:429-435



PATIENT

Walter O'Shannon

SPECIES

Canine

BREED

Chihuahua

SEX

Male Neutered

AGE

13 years

WEIGHT

7lbs

INTERPRETED BY

Maggie Machen
Lamy, DVM, DACVIM
(Cardiology)

IMAGING PERFORMED BY

Jenna Walsh, CVT

HOSPITAL NAME

Hello Vet for Pets
LLC

REFERRING VET

Dr. Christensen

INVOICE

29213

DATE

2/23/23

Hansson et al, Vet Rad and Ultrasound 2002 Bonagura et al. Echocardiography: principles of interpretation, Vet Clin North Am 15:1177, 1995	25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
	30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
	35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
	40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
	50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Chronic degenerative valve disease causing severe mitral and mild to moderate tricuspid regurgitation. The LA is severely dilated indicating a high risk for clinical signs going forward. Moderate pulmonary hypertension is noted, which is likely secondary to chronic LA pressure elevation. No additional concurrent issues such as systolic dysfunction are documented.

With this degree of left heart changes, the risk for spontaneous congestive heart failure is elevated and it is reasonable to continue full cardiac supportive medications are indicated as below. The use of Sildenafil could be debated in this case. Reported lethargy/twitching is unlikely to be related, unless the symptoms occur primarily with exertion. Given the unusual complaint, reasonable to initiate at this time as below. No arrhythmias are appreciated and this is considered unlikely in this signalment. A holter could be considered if any syncope develops.

Assessment of progression in the future will help predict long term outcome, however prognosis is guarded at this stage (late B2/C). Unfortunately, the patient will always be at risk for recurrent CHF, development of arrhythmias/LA tear, syncope and/or sudden death in the future.

Close monitoring for development of associated clinical signs (development of a cough, labored breathing, exercise intolerance or worsening collapse episodes) is recommended. Monitoring of sleeping breathing rates is recommended as the best way to screen for CHF at home.

Elective anesthesia is not advised, as there is high risk for complication. If necessary, cardiac protective drug choices (opioid/benzodiazepine premedication, propofol or alfaxalone induction, iso or sevoflurane gas) are recommended. Pre-oxygenate for 5-10 minutes prior to induction and recover in O2 cage. Monitor for arrhythmias, hypotension, and hypoxia both intra and post-operatively and intervene as necessary. Moderate IV fluid restriction is recommended to avoid fluid overload. Avoid heart rate stimulating drugs such as atropine unless clinically indicated.

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit.

PLAN

A screening BP is recommended. Administer Lasix 1mg/kg PO q12h. Administer Pimobendan 0.3mg/kg PO q12h. Institute ACE-I (benazepril or enalapril) 0.5mg/kg PO q12h pending BP >130mmHg. Institute spironolactone 1-2mg/kg PO q12h. Institute Sildenafil 1-2mg/kg PO q12h.

Monitor renal values in 1-2 weeks, then every 3-4 months lifelong to ensure tolerance of medications.

A recheck echocardiogram is recommended in 4-6 months to screen for progression, sooner if clinical signs arise.



PATIENT

Walter O'Shannon

SPECIES

Canine

BREED

Chihuahua

SEX

Male Neutered

AGE

13 years

WEIGHT

7lbs

INTERPRETED BY

Maggie Machen Lamy, DVM, DACVIM (Cardiology)

IMAGING PERFORMED BY

Jenna Walsh, CVT

HOSPITAL NAME

Hello Vet for Pets LLC

REFERRING VET

Dr. Christiensen




INVOICE

29213

DATE

2/23/23

IMAGES



The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance please contact me.

Maggie Machen Lamy, DVM
 Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
 info@sonopath.com